Senate Sends Strong Letter to FDA about Duchenne Therapies

Bipartisan Group of Senators Urge FDA to Utilize All Available Tools to Speed Access to Promising Duchenne Therapies


On Friday April 15th, U.S. Senators Roger Wicker, (R-MS) and Amy Klobuchar, (D-MN), sent a bipartisan letter to the U.S. Food and Drug Administration (FDA) urging the agency to use all available resources and authorities to accelerate the process of getting safe and effective treatments to patients diagnosed with Duchenne muscular dystrophy. 

The Senators were joined by 22 of their Senate colleagues in a bipartisan showing of support of our community. The result was thanks to YOUR EFFORTS reaching out to your US Senators asking them to sign on. Take a minute today to thank them! 


This letter is similar to the letter sent by 109 US House members earlier this year. With this letter now sent, both the House and Senate have communicated a strong message to the FDA about the need to use every possible tool at their disposal to speed access to promising Duchenne therapies, on the eve of our next Advisory Committee Meeting when eteplirsen takes center stage.    

  • Ayotte (NH)
  • Wicker (MS)
  • Klobuchar (MN)
  • Warren (MA)
  • Rubio (FL)
  • Markey (MA)
  • Schumer (NY)
  • Bennet (CO)
  • Barrasso (WY)
  • Cassidy (LA)
  • Lankford (OK)
  • Blumenthal (CT)
  • Collins (ME)
  • Murphy (CT)
  • Cotton (AR)
  • Capito (WV)
  • Sessions (AL)
  • Boxer (CA)
  • Brown (OH)
  • Menendez (NJ)
  • Cantwell (WA)
  • King (ME)
  • Coons (DE)
  • Murkowski (AK)

*We are also grateful to Senators Johnson, Carper, Donnelly and Coats for sending a similar letter to the FDA earlier this year.

Views: 903


You need to be a member of PPMD Community to add comments!

Join PPMD Community

Need help using this community site? Visit Ning's Help Page.



© 2021   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service